Schizophrenia
Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
UnknownNCT04892199
Official study titleDoes the Glucagon-like Peptide-1 Receptor Agonist Semaglutide Prevent Deterioration of Metabolic State in Prediabetic or Diabetic Patients With Schizophrenia Treated With the Antipsychotic Compounds Clozapine or Olanzapine?
Current recruitment status is unconfirmed.
Multiple locations, including AarhusSchizophreniaMedication studyAges 18–65
- Countries
- Denmark
- Sponsor
- Anders Fink-Jensen, MD, DMSci
CompletedNCT01035996
This study has finished and is no longer accepting participants.
In BaltimoreSchizophreniaObservational studyAges 18–50
- Countries
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
CompletedNCT00206960
What is this study about?This study assessed thinking abilities.
This study has finished and is no longer accepting participants.
Multiple locations, including CopenhagenSchizophreniaMedication studyAges 18–45
- Countries
- Denmark
- Sponsor
- Birte Glenthoj
CompletedNCT00580125
What is this study about?This study evaluated the safety and effectiveness of PF-00217830 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveSchizophreniaMedication studyAges 18+
- Countries
- United States, India, Russia, + 1 other
- Sponsor
- Pfizer
CompletedNCT01041092
What is this study about?This study evaluated the safety and effectiveness of raloxifene for people with schizophrenia.
This study has finished and is no longer accepting participants.
In Esplugues de LlobregatSchizophreniaMedication studyAges 40+
- Countries
- Spain
- Sponsor
- Fundació Sant Joan de Déu
TerminatedNCT00570063
What is this study about?This study evaluates the safety and effectiveness of PF-02545920 for people with schizophrenia.
This study ended early.
Multiple locations, including GlendaleSchizophreniaPlacebo comparisonAges 18–99
- Countries
- United States
- Sponsor
- Pfizer
CompletedNCT01338298
Official study titleDouble-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia
This study has finished and is no longer accepting participants.
In CatonsvilleSchizophreniaMedication studyAges 18–50
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
CompletedNCT02918630
This study has finished and is no longer accepting participants.
In HoustonSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
CompletedNCT03730857
Official study titleEarly Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18–65
- Countries
- Sponsor
- Calo Psychiatric Center
TerminatedNCT03852706
Official study titleA Randomized Controlled Pilot Trial of Low-resolution Brain Electromagnetic Tomography (LORETA) Neurofeedback Training for Treatment-resistant Auditory Verbal Hallucinations in Schizophrenia
This study ended early.
In DublinSchizophreniaInterventional studyAges 18+
- Countries
- Ireland
- Sponsor
- University of Dublin, Trinity College
CompletedNCT00893256
Official study titleProspective Double-Blind Randomized Comparison Study of Improvement in Negative Symptoms With Risperidone vs Risperidone +Citalopram Combination Therapy in Schizophrenia--a Clinical Study
This study has finished and is no longer accepting participants.
In BangaloreSchizophreniaMedication studyAges 17–50
- Countries
- India
- Sponsor
- National Institute of Mental Health and Neuro Sciences, India
UnknownNCT06505668
Official study titleEffect Of Atenolol Versus Ivabradine On Heart Rate Variability In Treatment Resistant Schizophrenia Patients On Clozapine With Tachycardia: A Randomized Control Trial.
Current recruitment status is unconfirmed.
In BhubaneswarSchizophreniaMedication studyAges 18–60
- Countries
- India
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
